UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): October 21, 2002

                      PROHEALTH MEDICAL TECHNOLOGIES, INC.
                      ------------------------------------

             (Exact name of registrant as specified in its charter)


           Nevada                        2 90519                 59-2262718
----------------------------            -----------          -------------------
(State or other jurisdiction            Commission              (IRS Employer
      of Incorporation)                 File Number          Identification No.)


        211 West Wall Street, Midland, Texas           70701-4556
      ----------------------------------------         ----------
     (Address of principal executive offices)         (Zip Code)



       Registrant's Telephone Number, including area code: (915) 682-1761

         (Former name or former address, if changed since last report.)




                                    FORM 8-K

ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.

SEE ITEM 5.

ITEM 5. OTHER EVENTS.

A.  Applied DNA Sciences, Inc. ("ADNAS")
------------------------------

ProHealth Medical Technologies, Inc. ("ProHealth" or "the Registrant") and ADNAS
effectuated a Plan and Agreement of Reorganization in accordance with 368(a)1(B)
of the  Internal  Revenue  Act on October 21,  2002,  wherein all of the 100,000
issued  and  outstanding  Common  Stock  shares  of  ADNAS  were  exchanged  for
11,000,000  shares  of  the  Registrant's  Common  Stock.  The  exchange  ratio,
therefore,  was one hundred ten (110) shares of ProHealth Medical  Technologies,
Inc.  Common  Stock for each  single (1) share of  Applied  DNA  Sciences,  Inc.
(110:1).

Upon the effectuation of the Reorganization,  the constituent  companies drafted
Articles of Merger  which will be filed  immediately  with the states of Nevada.
Once those  Articles are accepted  and returned  stamped as filed,  Glenn Little
will resign as President and Director,  Matthew Blair will resign and Secretary,
Treasurer  and  Director  and  Lawrence  Lee  will  become  the  new  President.
Contemporaneous with the resignation of Messrs.  Little and Blair, Mr. Lee shall
be appointed to the Board of Directors.

Pursuant to the Plan and  Agreement of  Reorganization  for the  acquisition  of
ADNAS,  the transaction was made effective as of 10:00 a.m. on October 21, 2002.
To effectuate the acquisition, both of the shareholders of ADNAS (being Lawrence
Lee  and RHL  Management,  Inc.)  and the  Registrant  entered  into a Plan  and
Agreement  of  Reorganization  pursuant to section  368(a)1(B)  of the  Internal
Revenue Code. It is the intention of the Registrant to immediately merge its new
wholly  owned  subsidiary  with and into  itself,  and then  change  its name to
Applied DNA  Sciences,  Inc. In the  stock-for-stock  exchange,  the  Registrant
acquired all of the issued and outstanding capital stock of ADNAS for a total of
11,000,000  shares of ProHealth Medical  Technologies,  Inc.

On or about October 10, 2002, ADNAS signed an exclusive  license  agreement with
Biowell Technology,  Inc., a DNA based anti- counterfeiting  technology company,
which  agreement  has been  deemed  valuable  by  ADNAS  and  ProHealth  Medical
Technologies,  Inc. Upon the Registrant's receipt of the filed short form merger
and name change  documents from t he Nevada  Secretary of State,  the Registrant
will file its first amendment to this 8K to reflect the completion of the merger
transaction.


ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

ProHealth Medical Technologies,  Inc. will be filing the financial statements by
amendment  within 60 days,  as permitted by the  instructions  of this Form 8-K,
Item 7.(a)(4). That amendment will be the second one made to this current report
on Form 8K.

         Exhibit Index

         2.1      Plan and Agreement of Reorganization  with the Shareholders of
                  Applied DNA Sciences, Inc.


         10.1     (Exhibit  A to  the  Plan  and  Agreement  of  Reorganization)
                  Exclusive License Agreement between Biowell  Technology,  Inc.
                  and Applied DNA Sciences, Inc.


                                   SIGNATURES
                                   ----------

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.



                                    PROHEALTH MEDICAL TECHNOLOGIES, INC.




                                                    /s/ Glenn Little
                                                  ------------------------------
                                                  Glenn Little, Former President